Horizon Therapeutics plc (Nasdaq: HZNP) today announced its expansion into the Middle East with the opening of its Technical Scientific Office (TSO) in Riyadh, Saudi Arabia.
Horizon Therapeutics’ first TSO in the Middle East is part of the company’s commitment to those living with rare, autoimmune and severe inflammatory diseases across the world.
“There is a significant unmet medical need in Saudi Arabia to provide healthcare solutions to patients living with rare, debilitating diseases,” said Fábio Ivankovich, vice president, international operations and general manager, Latin America and Canada, Horizon. “The opening of our TSO in Riyadh is the first step in enabling us to provide our medicines to meet the needs of those patients.”
“We proudly welcome Horizon Therapeutics as it opens its Middle East TSO in the heart of Riyadh, building upon Saudi Arabia’s advancements in the region’s growing biotechnology community,” said Yasser Naghi, CEO of Cigalah Healthcare Company. “In line with Vision 2030, our strategic partnership is set to transform the rare disease community in Saudi Arabia and provide patients with increased access to healthcare solutions.”
Horizon is a global biotechnology company focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: We apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.